Seok-Jin Kim

Affiliations: 
School of Energy & Chemical Engineering Ulsan National Institute of Science and Technology, Ulsan, South Korea 
Google:
"Seok-Jin Kim"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Sim J, Takayama T, Cho J, et al. (2019) Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997-2016: An observational study. Medicine. 98: e17641
Han GF, Shi XM, Kim SJ, et al. (2019) Dissociating stable nitrogen molecules under mild conditions by cyclic strain engineering. Science Advances. 5: eaax8275
Kim SJ, Kang D, Kim I, et al. (2019) Impact of fear of cancer recurrence on survival among lymphoma patients. Psycho-Oncology
Cho J, Kim SJ, Park WY, et al. (2019) Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc
Tan KM, Chia B, Lim JQ, et al. (2019) A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study. Scientific Reports. 9: 14961
Oh SY, Kim WS, Kim JS, et al. (2019) Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. Cancer Communications (London, England). 39: 58
Ryu D, Kim SJ, Hong Y, et al. (2019) Alterations in the transcriptional programs of myeloma cells and the microenvironment during extramedullary progression affect proliferation and immune evasion. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Kim SJ, Yoon DH, Kim JS, et al. (2019) Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial. Cancer Research and Treatment : Official Journal of Korean Cancer Association
Kim D, Lee GY, Choi JO, et al. (2019) Prognostic values of novel biomarkers in patients with AL amyloidosis. Scientific Reports. 9: 12200
Lee YJ, Moon JH, Sohn SK, et al. (2019) Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma. Bone Marrow Transplantation
See more...